Leerink Partners Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has downgraded Theravance Biopharma (NASDAQ:TBPH) from Outperform to Market Perform and lowered the price target from $15 to $10.
August 06, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and reduced the price target from $15 to $10.
The downgrade from Outperform to Market Perform and the significant reduction in the price target from $15 to $10 by Leerink Partners is likely to negatively impact investor sentiment and the stock price of Theravance Biopharma in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100